Trending Topic

A dynamic close-up visualization of red blood cells and glucose molecules inside a human artery
8 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked
Jennifer N Clements, Kennedy Howard, Emory Moss

Approximately 20–34% of hospitalized patients have a diagnosis of diabetes, while many others experience stress hyperglycaemia, both increasing the occurrence of dysglycaemia in the hospital.1 Hyperglycaemia is associated with increased infection rates and higher mortality rates. Conversely, hypoglycaemia can lead to adverse neurological outcomes, prolonged hospital stays, as well as increased mortality.1 In spite of current guidelines […]

Hiddo Heerspink, ADA 2022: Current treatment options for chronic kidney disease in type 2 diabetes and the unmet needs

3 mins
Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Jun 27th 2022

The current treatment options for chronic kidney disease in patients with type 2 diabetes is discussed by Professor Hiddo Heerspink (University Medical Center Groningen, Groningen, Netherlands). Also discussed is the mechanism of tirzepatide, a novel once-weekly medication, which has shown to improve kidney outcomes in adults with type 2 diabetes who have increased cardiovascular risk.

Professor Hiddo Heerspink presented an abstract entitled ‘Effects of Tirzepatide vs. Insulin Glargine 100 U/mL on Kidney Outcomes in Participants with Type 2 Diabetes in SURPASS-4‘ at the 82nd American Diabetes Association Scientific Session, June 3-7, 2022.

Questions: 

  1. Why is it so important to control the progression of chronic kidney disease (CKD) in people with type 2 diabetes? (0:22)
  2. Despite current treatment options, what unmet needs exist in the effective management of CKD in people with type 2 diabetes? (0:59)
  3. What is the mechanism of action of tirzepatide, and how does this differ from currently available therapies in this indication? (1:50)

Disclosures: Hiddo Heerspink is a consultant for: AstraZeneca, Bayer, Boehringer Ingelheim, Chinook, CSL Behring, Dimerix, Eli Lilly, Janssen, NovoNordisk and Travere. Hiddo Heerspink has received grant/research support from AstraZeneca, Boehringer Ingelheim and Novo Nordisk and is a speaker’s bureau participant with AstraZeneca.

Support: Interview and filming supported by Touch Medical Media. Interview conducted by Danielle Crosby.

Filmed as a highlight of ADA 2022.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup